Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Nervous System Diseases

Rare Diseases

Sarcoma

Liposarcoma

Histiocytoma, Malignant Fibrous

Testicular Neoplasms

Chondrosarcoma

Fibrosarcoma

Histiocytoma

Leiomyosarcoma

Rhabdomyosarcoma

Sarcoma, Synovial

Neurofibrosarcoma

Sarcoma, Alveolar Soft Part

Neoplasms, Connective and Soft Tissue

Myosarcoma

Neoplasms by Histologic Type

Soft Tissue Sarcoma

Synovial Sarcoma

Malignant Peripheral Nerve Sheath Tumor

All Drugs and Chemicals

Vaccines

Immunomodulating Agents

Immunologic Factors

Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens

Autologous dendritic cell vaccine

Yuriy Komarov, PhD

The purpose of this study is to achieving a six-month progression free survival (PFS) of patients receiving autologous dendritic cell vaccine (ADKV) loaded with allogeneic tumor lysate expression of cancer-testis antigens (CTA) in patients with soft tissue sarcomas

Vaccination is carried out on the planned days ± 3 days

1. All examinations must be performed before the vaccine is administered.

   * Full physical examination.
   * Assessment of vital signs (blood pressure, temperature, heart rate), the general condition of the patient and physical activity.
   * Evaluation of concomitant therapy.
   * Assessment of vital signs.
   * Laboratory safety and immunological indicators
   * Assessment of adverse events, symptoms and syndromes of the disease.
2. Introduction of CV in accordance with the dose determined for a given vaccination (see section 9.2. - procedures for delivery and use)
3. After administration, patients are observed for at least 1 hour. An assessment of vital indicators. Undesirable effects detected at the introduction are recorded.

Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma

Non-randomized Single-center Study Phase II Evaluating the Efficacy and Toxicity of Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma

Achieving a six-month time to progression (PFS) 40% of patients receiving ADKV loaded with allogeneic tumor lysate expressing PTA in patients with soft tissue sarcomas

The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In a clinical trial, measuring the progression-free survival is one way to see how well a new treatment works

The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that half of the patients in a group of patients diagnosed with the disease are still alive. In a clinical trial, measuring the median overall survival is one way to see how well a new treatment works

The percentage of patients whose cancer shrinks or disappears after treatment.

Сhanging level of T lymphocytes subpopulation in peripheral blood

N.N. Petrov National Medical Research Center of Oncology

Skin and Connective Tissue Diseases

Hemangiosarcoma

Neoplasms, Vascular Tissue

Neoplasms, Fibrous Tissue

Neoplasms, Connective Tissue

Antineoplastic Agents

Gemcitabine

Docetaxel

Bevacizumab

Lenograstim

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Antimetabolites

Tubulin Modulators

Antimitotic Agents

Patients will receive bevacizumab at 15 mg/kg on day 1 of each 21-day cycle intravenously over 30 minutes followed by a one hour (+30/-15 min) break. For cycles 1 through 6, gemcitabine will be administered at 900 mg/m2 over 90 minutes on day 1 and 8 of a 21-day cycle. Docetaxel will be administered at 75 mg/m2, over 60 minutes, on day 8. This will be followed by either 5 days of filgrastim or a single injection of pegfilgrastim. For cycles 7 and beyond, gemcitabine will be given at 800 mg/m2 over 30 minutes on day 1 and 8; docetaxel will be given at 35 mg/m2 over 30 minutes, also on days 1 and 8.

gemcitabine

docetaxel

bevacizumab

William Tap, MD

The purpose of this study is to test whether an experimental drug called bevacizumab given together with gemcitabine and docetaxel, a standard chemotherapy regimen for sarcoma, can help sarcoma patients. This trial will examine what effects, good and/or bad the combination of gemcitabine, docetaxel and bevacizumab has on sarcoma.

Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes

Phase II Trial Of Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes

Overall Objective Response will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma	NCT01883518	Sarcoma Neoplasms, Conn...	Autologous dend...	18 Years -	N.N. Petrov National Medical Research Center of Oncology
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes	NCT00887809	Sarcoma Leiomyosarcoma Malignant Fibro... Histiocytoma Angiosarcoma	gemcitabine docetaxel bevacizumab	18 Years - 75 Years	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for histiocytoma

Every month we try and update this database with for histiocytoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.